Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study

BackgroundIn the phase 3 SELECT study, lenvatinib significantly improved prognostic outcomes vs. placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, toxicity of lenvatinib is sometimes considerable and requires frequent dose interruptions and modification...

Full description

Bibliographic Details
Main Authors: Chihiro Matsuyama, Tomohiro Enokida, Yuri Ueda, Shinya Suzuki, Takao Fujisawa, Kazue Ito, Susumu Okano, Makoto Tahara
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
lenvatinib
thyroid cancer
oral anticancer agent
VEGF tyrosine kinase inhibitor
adverse events
planned drug holidays
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1139659/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1139659/full

Similar Items